Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis

Inclusion Criteria: * Have completed all 12 weeks of Protocol Z102-008 or discontinued after participating in at least 6 weeks of the randomized withdrawal portion of Z102-008 for acceptable reasons * Have met all inclusion/exclusion criteria for enrollment into Protocol Z102-008 * Have been on DMARD therapy for at least 90 days and have been on a stable DMARD dose without dosage adjustment or modification for 6 weeks prior to enrollment into Protocol Z102-008, and be able to maintain the same dose of conventional DMARD therapy during Protocol Z102-009 participation Exclusion Criteria: * Did not complete 6 weeks of the double-blind section of Protocol Z102-008, or was discontinued from Protocol Z102-008 for reasons of an AE, protocol violation, or non-compliance * Active cardiovascular disease, unless well controlled by appropriate treatment, for a minimum of 3 months prior to screening for enrollment into Protocol Z102-008 * Currently taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg * Taking oral steroids at a daily prednisone dose, or the equivalent, of \>10 mg/day within the past 2 weeks * Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering study Protocol Z102-008 or Protocol Z102-009, at any time during the study, or be anticipated to be given at any time during the study * The need to continue the use of one or multiple NSAIDs at the same time, or use acetaminophen on a chronic basis * All opiate use is prohibited. * Use of any other medications or herbs or non-pharmacological treatments (e.g., acupuncture) used for the treatment of pain is prohibited * Has, or has had, any active severe infections or recent invasive surgical procedures within 30 days of Protocol Z102-008 or Protocol Z102-009 initiation * HIV, hepatitis B, or hepatitis C infection * Has undergone administration of any investigational drug within 30 days of study * All biologic agents are excluded for 90 days prior to Screening and during the conduct of Protocol Z102-008, and Protocol Z102-009 * Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of Protocol Z102-008 Screening or Protocol Z102-009 initiation, or at any time during participation in study Protocol Z102-008 * Has a history of hypersensitivity reaction to glucocorticoids and/or dipyridamole * Known or suspected history of alcohol or drug abuse within 2 years prior to Screening for Protocol Z102-008 * Has any other medical condition which may interfere with the conduct of this study in the opinion of the investigator